Less Ads, More Data, More Tools Register for FREE

Pin to quick picks3i Group Regulatory News (III)

Share Price Information for 3i Group (III)

Share Price is delayed by 15 minutes
Get Live Data
2,209.00    19.00 (0.87%)
Bid:
2,212.00
Ask:
2,214.00
Spread: 2.00 (0.09%)
Market Cap: £22.41b
III Live PriceLast checked at - London Stock Exchange

Intraday 3i Group Share Chart

Completion of acquisition

11 Nov 2013 07:00

RNS Number : 6584S
3i Group PLC
11 November 2013
 



11 November 2013

 

3i announces the completion of the acquisition of Barclays Infrastructure Funds Management Limited

 

3i Group plc ("3i") today announces the completion of the acquisition from Barclays Bank plc of Barclays Infrastructure Funds Management Limited, its European infrastructure fund management business.

The business currently manages two active unlisted funds that invest in UK and European PPP and energy projects and has assets under management of approximately £780 million.

Barclays Infrastructure Funds Management Limited will be renamed 3i BIFM Limited ("3i BIFM") and will be incorporated into 3i's existing infrastructure investment business led by Managing Partner Cressida Hogg. 3i BIFM's activities will continue to be led by Nigel Middleton and Andy Matthews who along with Stéphane Grandguillaume will join as Partners in 3i's infrastructure business. The 22-strong team will be based at 3i's offices in London and Paris. 

The completion of this acquisition represents a significant milestone in the implementation of 3i's strategy, demonstrating 3i's commitment to the growth of its infrastructure business and reaffirming its objective to increase third-party fee income by growing assets under management. 3i intends to leverage the enhanced platform to bring incremental deal flow to 3i Infrastructure plc and raise new funds. The acquisition will broaden the capabilities and expertise of 3i's infrastructure investment team, expanding its access to the growing PPP and energy project market across Europe.

 

-Ends-

For further information, contact:

 

Silvia SantoroInvestor Relations Director

Tel: +44 20 7975 3258

Email:silvia.santoro@3i.com

 

Kathryn van der KroftCommunications Director

Tel: +44 20 7975 3021

Email:kathryn.vanderkroft@3i.com

 

 

 

About 3i Group

3i is a leading international investor focused on mid-market private equity, infrastructure and debt management across Europe, Asia and the Americas. For further information, please visit: www.3i.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQDMMMMVMFGFZG
Date   Source Headline
5th Jun 20264:00 pmRNSHolding(s) in Company
2nd Jun 20264:24 pmRNSDirector/PDMR Shareholding
2nd Jun 20263:37 pmRNSDirector/PDMR Shareholding - Amendment
1st Jun 20264:28 pmRNSDirector/PDMR Shareholding
1st Jun 20267:00 amRNSTransaction in Own Shares
29th May 20265:42 pmRNSTotal Voting Rights
29th May 20265:38 pmRNSAdmission to Trading
27th May 202610:42 amRNSNotice of AGM
26th May 20267:00 amRNSTransaction in Own Shares
22nd May 202612:29 pmRNSDirector/PDMR Shareholding
21st May 20267:40 amRNSDoc re. 2026 Annual Report and Accounts
19th May 20262:28 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransaction in Own Shares
15th May 202610:24 amRNSDirector/PDMR Shareholding
14th May 202610:41 amRNSHolding(s) in Company
14th May 20267:02 amRNSCommencement of Share Buyback Programme
14th May 20267:00 amRNSResults for the year to 31 March 2026
1st May 202612:00 pmRNSDirector/PDMR Shareholding
30th Apr 20263:34 pmRNSTotal Voting Rights
30th Apr 20263:31 pmRNSAdmission to Trading
7th Apr 202612:33 pmRNSHolding(s) in Company
1st Apr 20269:53 amRNSPortfolio Update
1st Apr 20269:36 amRNSDirector/PDMR Shareholding
31st Mar 20262:30 pmRNSTotal Voting Rights
31st Mar 20262:29 pmRNSAdmission to Trading
31st Mar 202611:37 amRNSDirector/PDMR Shareholding
30th Mar 20267:00 amRNSDirector/PDMR Shareholding
27th Mar 20263:07 pmRNSAdmission to Trading
26th Mar 20267:00 amRNSAction Capital Markets Seminar & portfolio update
23rd Mar 202612:11 pmRNSHolding(s) in Company
2nd Mar 202612:18 pmRNSDirector/PDMR Shareholding
27th Feb 20264:00 pmRNSTotal Voting Rights
3rd Feb 202610:20 amRNSHolding(s) in Company
3rd Feb 202610:17 amRNSDirector Declaration
30th Jan 20262:24 pmRNSDirector/PDMR Shareholding
30th Jan 20261:47 pmRNSTotal Voting Rights
29th Jan 202612:19 pmRNSDirector/PDMR Shareholding
29th Jan 20267:00 amRNSFY2026 Q3 performance update
7th Jan 20262:06 pmRNSDirector/PDMR Shareholding
6th Jan 20261:53 pmRNSTotal Voting Rights
2nd Jan 202611:06 amRNSPortfolio Update
9th Dec 20251:11 pmRNSBlock listing Interim Review
4th Dec 20252:12 pmRNSDirector/PDMR Shareholding
1st Dec 20251:25 pmRNSDirector/PDMR Shareholding
28th Nov 20254:24 pmRNSTotal Voting Rights
20th Nov 20259:59 amRNSDirector/PDMR Shareholding
18th Nov 20252:23 pmRNSDirector/PDMR Shareholding
17th Nov 202512:50 pmRNSDirector/PDMR Shareholding
17th Nov 202512:48 pmRNSDirector/PDMR Shareholding
14th Nov 20254:20 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.